chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient's mom say first vaccine was 8-2-07.  (Patient got sick on 8-31-07.  (Vomiting, diarrhea x 2 days) no doctor visit).  Second vaccine 10-12-07.  Patient had abd pain, pain 1 week later and was in hospital.  Oct 14 left hospital.  Last dose 2-26-08 - patient got sick March 7th and pain now has warts on knees.  9/15/2008 MR received for 3 admssions: 10/16-20/07 with D/C Dx:  Abdominal pain with persistance after multiple evaluations. 10/27-30/2007 with D/C DX: Nausea, Vomiting, Abdominal Pain, mild non-erosive gastritis.  helicobacter pylori. Recent appendectomy.  hematuria, need outpt f/u. Constipation. 02/8-15/2008 with D/C DX:  Intractable nausea and vomiting.  Severe epigastric pain NOS. Mild ileus. Pt initially presented to ER 10/16/07 with c/o RLQ abd pain, nausea, decreased appetite and fever.  W/u (-) but sent for laparoscopy with appendectomy. D/C stable.  Returned 10/27/07 and admitted with chest pain, nausea, vomiting and abd pain. Required PCA for pain mgmt. Sx improved with PPI and Carafate and D/c. Returned 2/8/08 with recent return of sx, now with epigastric pain. pt awakens from sleep screaming in pain. Again required PCA. Etiology of sx unclear per GI consult.
Swelling and redness of the thigh and knee are a localized inflammatory reaction to the flue vaccine on 9/28/18 (reported by Hospital). TYLENOL should be effective for pain, and BENADRYL will be helpful if your child develops itching (hospital treatment).
Guillain-Barre Syndrome, pain, numbness, tingling in feet and legs, inability to walk, numbness in fingers. Hospitalized in ICU and rehab, treated with IVIG, pain medication, muscle relaxants.
Symptoms: cold&clammy, lethargic. 2:24pm-per client's son, Paramedics assessed client on site, vital signs: BP 51/40, pulse 56,O2sat 98, blood glucose 107.  2:27pm Pt. transport from passenger side of personal vehicle to ambulance via stretcher. 2:35pm per Paramedics "client was placed in Trendelendurg position and 500 cc of normal saline given."  2:45pm Final BP 137/87, pulse 68. 2:47pm Client refused to be transported to hospital. Fire Rescue arrived on scene to transport to hospital.  Per client, "No".  3:00pm Per Paramedics client stable no further.  Evaluation needed client signed a released form.  3:05pm Client released for home at 3:05pm accompanied by son.
20 minutes after receiving the vaccination the resident started to not feel well. She said she felt very far away and just kept repeating I don't feel well. She was diaphoretic and her chest was very red and she kept scratching and rubbing it at it. I asked if she wanted IM Benadryl or epipen and she at first denied. She also said she felt like she needed to focus on her breathing. At this time we decided it was best to administer Epipen x 1 dose. Immediately after she felt better. She was observed for another 30 minutes and then went home. at 7:17pm I called and spoke with her. She said her arm was sore and that her oxygen levels were about 88-89% which is low for her but she said she felt fine and is currently working right now.
"Tingling sensation" was felt on left wrist area and arms.  Afterwards, itching and a rash developed on the wrist, arms, back, breasts, thighs, and legs.  These symptoms started later, during the same day the vaccine was given.  Rubbing alcohol was applied to the various sites to try to help relieve the itching.
Starting the end January 2021, increased incidence in PVC's. This continued for several months--occasional  PVC's.  Dr. did an EKG, 48 hour Holter monitor study was done, also referral to cardiology.  Before cardiology appointment, near end of July for 7-10 days,  frequency of PVC's really increased.  Another Holter study was ordered BUT they were not able to get me in for the Holter monitor for 10 days. By the time I was able to get the monitor the frequent PVC's had decreased to occasional. Saw cardiology end of September. He ordered an echocardiogram which was done early November.  Results showed a decrease in my ejection fraction to 45%. No history of high blood pressure, diabetes or myocardial infarction.
This spontaneous report received from a patient, concerned a patient of unspecified age and gender. Medical history, weight, height, concomitant medications and concurrent conditions not reported. The patient received COVID-19 vaccine ad26.cov2.s (suspension for injection, route of admin and batch/lot number: not reported) dose, start therapy date: not reported, for immunization. Unable to perform follow-up to request batch/lot numbers. On an unspecified date, patient experienced some residual, left over symptoms. The action taken with COVID-19 vaccine ad26.cov2.s: not applicable. The patient has not recovered.
DEVELOPED GOOSEBUMP LOOKING BUMPS ON ARMS, STOMACH, LEGS. PT IS DARK SKINNED, SO DOES NOT LOOK RED. NOT WARM TO TOUCH, BUT RATHER SKIN FEELS COOL. PT DID HAVE A SMALL FEVER 99.3. ATYPICAL DERM RXN (NOT HIVES?) RPH COUNSELED FOR PT TO TAKE ANTIHISTAMINE (BENADRYL MOST QUICK ACTING) AND MONITOR. CHANGES IN PAIN, LOCATION OR SIZE, OTHER S/SX. FOLLOW UP WITH RPH OR PRESCRIBER. ALSO OK TO TAKE TYLENOL FOR FEVER IF DISCOMFORT.
Diagnosed with Lyme borreliosis; This spontaneous case was reported by a consumer and describes the occurrence of LYME DISEASE (Diagnosed with Lyme borreliosis) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced LYME DISEASE (Diagnosed with Lyme borreliosis) (seriousness criterion medically significant). At the time of the report, LYME DISEASE (Diagnosed with Lyme borreliosis) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.  No treatment information was provided.  Based on current available information and the temporal association between product use and the start date of the event a causal relationship is unlikely.; Sender's Comments: Based on current available information and the temporal association between product use and the start date of the event a causal relationship is unlikely.
This spontaneous report as received from a pharmacist via Poison & Drug Center (MRF# US16-057657) refers to several patients of unknown age.   This pharmacist reported that an unknown number of patients of unknown sex and age were administered one vial of ZOSTAVAX ( lot # M019646, EXP18-JUL-2017, once, subcutaneous) on unknown dates within the past 6 months in 2016 for prevention of shingles. Concomitant medications, relevant laboratory data, and past medical history were unknown for all patients. The pharmacist reported several patients complaining of itching, tingling, numbness, and a ring around the injection site after she administered ZOSTAVAX. It was unknown if the itching, tingling, numbness and ring around the injection site was treated but it did resolve for all of the patients. The causality between the events and ZOSTAVAX was not reported. Additional information has been requested.
mom stated pt had high pitched cry a couple of hr p/vax given;t101 & lt leg was swollen;no tx;
Had back pain, tingling in feet went to my pcp on may 13th and was treated for pinched nerve. Started having muscle fatigue and paralysis in legs so went to ER on the 16th and was diagnosed with bell's palsy and possible pinched nerve. Advised to see a neurologist and orthopedic dr
This case was reported by a consumer via call center representative and described the occurrence of swelling in a adult female patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, 5 days after receiving SHINGRIX, the patient experienced swelling, erythema and pain. On an unknown date, the outcome of the swelling, erythema and pain were unknown. It was unknown if the reporter considered the swelling, erythema and pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. However, it could be 74 or 75 years. The reporter was friend of patient. The patient received SHINGRIX on an unknown arm. The reporter did not know what date the patient received the vaccination or how soon after that these symptoms which occurred on the site of the arm where the vaccine was administered. The reporter had no further information about in which arm or the exact dosing administered or at what facility the vaccine was administered. The symptoms might have started within 5 or 6 days after receiving the vaccine, but the reporter was not sure. The patient was still experiencing the symptoms as of this past Sunday (on 29th April 2018), but the status of the symptoms was currently unknown to the reporter today. The reporter granted permission to be contacted with further related questions.
pt reported tinnitus and consulted dr who advised her it could be vaccine related as no other medications risks or changes. pt still has symptoms.
prescriber advised that there could be some injection site irritation. She has some irritation; Fever; Chills; This is a spontaneous report from a contactable consumer (parent). A 24-year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), via an unspecified route of administration on an unspecified date at single dose for immunization.  Medical history included Type 1 diabetic from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient received the injection on Tuesday and her prescriber advised that there could be some injection site irritation. She had some irritation, she also had fever and also had chills as well. The patient underwent lab tests and procedures which included body temperature: fever. The outcome of the events was unknown.   No follow-up attempts are needed. Information on Lot/batch number cannot be obtained. No further information is expected
loss of appetite; stomach pain; tiredness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient (Age: 71; Unit: Unknown) received bnt162b2 (BNT162B2), administration date 20Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DECREASED APPETITE (non-serious) with onset Mar2021, outcome "unknown", described as "loss of appetite"; ABDOMINAL PAIN UPPER (non-serious) with onset Mar2021, outcome "unknown", described as "stomach pain"; FATIGUE (non-serious) with onset Mar2021, outcome "unknown", described as "tiredness".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report as received from a physician via a company representative refers to a female patient of unknown age over 60 years old. Approximately in December 2014 (also reported as within the last two months) the patient was vaccinated with ZOSTAVAX (0.65 ml, once, subcutaneously, lot # not reported) and experienced an increased injection site reaction which resembled cellulitis and which measured about 6 inches in diameter after receiving ZOSTAVAX. Because cellulitis could not be ruled out, the patient was treated with an unspecified antibiotic and referred to an unspecified wound care facility where the patient was receiving treatment at the time of the report. The patient's outcome was reported as recovering. The patient sought medical attention and saw the physician. The relatedness between the event and ZOSTAVAX was not reported. Additional information has been requested.
COVID arm; Hot and little swelling; Injection site was pretty large; Injection site red again; Arm started to hearting again; Kind of hard; Burns a little bit; This spontaneous case was reported by a consumer and describes the occurrence of UNEVALUABLE EVENT (COVID arm), PAIN IN EXTREMITY (Arm started to hearting again), MUSCULOSKELETAL STIFFNESS (Kind of hard), BURNING SENSATION (Burns a little bit) and SWELLING (Hot and little swelling) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Feb-2021, the patient experienced PAIN IN EXTREMITY (Arm started to hearting again), MUSCULOSKELETAL STIFFNESS (Kind of hard), BURNING SENSATION (Burns a little bit), INJECTION SITE REACTION (Injection site was pretty large) and INJECTION SITE ERYTHEMA (Injection site red again). On an unknown date, the patient experienced UNEVALUABLE EVENT (COVID arm) and SWELLING (Hot and little swelling). At the time of the report, UNEVALUABLE EVENT (COVID arm), PAIN IN EXTREMITY (Arm started to hearting again), MUSCULOSKELETAL STIFFNESS (Kind of hard), BURNING SENSATION (Burns a little bit), SWELLING (Hot and little swelling), INJECTION SITE REACTION (Injection site was pretty large) and INJECTION SITE ERYTHEMA (Injection site red again) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent condition and concomitant medication were not reported. Since an unknown date in November 2015, the patients were vaccinated with improperly stored doses of VAQTA (strength, does, route, lot number and expiration date were not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Flu like symptoms 8-9 hours after injection; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms 8-9 hours after injection) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     Concurrent medical conditions included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms 8-9 hours after injection). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms 8-9 hours after injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication list was not provided. Treatment information was not provided.   Reporter did not allow further contact
8 days after my vaccine, I had to have my appendix removed.  Previous blood work (within a few months prior) showed zero issues.  Also, I never had an allergic reaction to steri-strips or surgical tape and ended up breaking out in a rash from shoulders to mid-thigh.  Finally, I never had cold sores and I had to treat cold sores for 8 days.
Aches and pain throughout body (similar to flu aches), fatigue, headache. Silo mar to when I had COVID
bleeding restarted; back pain identical to the pain during labor; This is a spontaneous report from a non-contactable consumer (patient). A 36-year-old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration on an unspecified date (batch/lot number and expiry date not reported) as single dose for covid-19 immunization. Medical history was none. The patient has no covid prior vaccination. The patient's concomitant medications were not reported. The patient informed that 2nd dose was received at the end of period (4th day) (unspecified). The following day (unspecified date), bleeding restarted and back pain identical to the pain during labor (so called "back labor"). The patient reported bleeding restarted was non-significant. The patient was asking to investigate if causes cramps or affects reproductive system. The patient was not covid tested post vaccination. The outcome of the events was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Pt had a flu shot and felt bone pain upon the administration of vaccine. Patient went home and waited for a few days and the pain still persisted. Patient returned to the store 2 weeks later with complaints of pain and some limited mobility in the left arm.
headaches, earaches, body aches, fever 99.7 to 101.1, nausea, dizziness, rouble sleeping, back aches,
Left arm sore upon administering. Around 5pm soreness increasing, ice used. 10pm at bedtime continued ice, unable to move arm, pain  radiating from shoulder to fingers. Midnight awoken due to pain, unable to move arm, nauseous, chills, feeling like I could pass out. Only able to sleep minimal due to pain. 4am still unable to use arm. 8am nauseated, zofran taken, crackers and Tylenol. 9am, still nauseous, arm soreness not worsening
This spontaneous report as received from a medical assistant refers to a 14 year old patient who on 09-JUL-2014, the patient was vaccinated with a dose of (Oka/Merck) Varivax (lot numbers reported as J012816, Exp. Date: 10-OCT-2015 and J009986, Exp. Date: 12-AUG-2015) .5 ml, subcutaneous and a dose of M-M-R II HSA (lot numbers reported as J002866, Exp. Date: 12-MAR-2015 and J008154 Exp. Date: 08-JUL-2015) that were improperly stored. Doses and routes were not reported. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.
For 2-3 weeks I was sick to my stomach. I had to take medicine in order for the nauesous to stop. I had to force myself to eat. It subsided when I went to an impatient facility.
Pt presents to ED from home with complaints of fatigue, decreased PO intake, and falls. Pt fell prior to coming to ED and hit his head. Pt states he is not on blood thinners.  Pt denies fever, chills, nausea, vomiting, diarrhea, abdominal pain, dysuria, cough, congestion, sore throat, dyspnea, chest pain, heart palpitations, or travel.  Pt does report his wife and daughter were diagnosed with COVID a few weeks ago.  Pt hemodynamically stable and afebrile on room air.  Pt COVID19 was positive.  Constitutional: Positive for fatigue. Negative for chills, fever and unexpected weight change.   Treatment: dexamethasone, remdesivir   Discharge Disposition/Condition Disposition: Home Condition: Stable (s/sx potential problems absent or manageable)
Patient received 2nd COVID-19 vaccine (Pfizer lot #EN6207) at 1:20pm. Patient was advised to wait for 30 minutes d/t possible mild allergic symptoms after first dose. At 20 minutes (1:55pm) patient presented from observation area to vaccinator, CMA who notified me. Patient reported itching and "tingling". Patient noted to be scratching and shaking a little bit. Lungs were clear. Over the next 2 minutes, patient developed splotchy rash on chest and was noted to be grabbing and scratching at her throat. She stated she felt like "a buzzing" was going through her body. At 1:57pm, I administer an EpiPen to the L thigh and rapid response overhead announcement was called. Stayed with patient until urgent care team arrived at 1:58 pm and took over care. At 2:03pm, urgent care team transported patient via wheelchair to UC for further monitoring.
This is a spontaneous report from a contactable pharmacist (patient). A 68-year-old male patient received PREVNAR 13, via an unspecified route of administration on 29Dec2018 at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient stated that he received the vaccine on 29Dec2018 and the next day he woke up with "lower stomach pain, diarrhea and a low grade fever". However on 04Jan2019 he broke out with a rash under his chin, neck, both arms and legs, and shoulder. He had "severe itching, was sensitive to touch and uncomfortable". He thought he had shingles but that was ruled out by his dermatologist, who told him it was dermatitis. He was prescribed a steroid cream. As per caller most of the rash has gone away but on his left breast there "a patch and looks like it's spreading". The outcome of the events was unknown. The information on the lot number and expiration date had been requested.
This spontaneous report as received from medical assistant regarding to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 29-FEB-2016, the patient was inadvertently administered with a dose of PROQUAD (Merck) (lot and dosing details unknown) which was reconstituted with expired diluent (lot L005459, expiry 18-FEB-2016). No adverse effects were reported. Product quality complaint (PQC) was not filed. Additional information has been requested.
Patient presented to the emergency department with tongue and throat swelling. According to hospital visit note,  approximately 15 minutes prior to arrival, pt had an unknown exposure and began developing swelling in his throat and tongue. He felt that it began affecting his breathing, and he immediately came into the Emergency Department. He was not having any rash, abdominal pain, vomiting, diarrhea, chest pain or palpitations, but was having some difficulty breathing.  He received epinephrine, Benadryl, Pepcid and steroids, and after a few minutes, he was felt to require intubation. Anesthesia was called for an airway alert. Attempts at oral intubation had failed and anesthesia then proceeded with fiberoptic nasotracheal intubation. Once the airway was secured, he was admitted to the Intensive Care Unit on a propofol drip for sedation and placed in restraints. Patient expired 07/19/19.
wife just tested positive for COVID-19; wife just tested positive for COVID-19; cough; congested head; sinus infection; yellow mucus; This is a spontaneous report from a contactable consumer(patient's husband). An 82-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, (Batch/Lot number was not reported), first dose via an unspecified route of administration on 26Mar2021 as SINGLE DOSE for covid-19 immunization. Patient medical history and concomitant medications were not reported. On an unspecified date the reporter stated that his wife just tested positive for COVID-19. Second dose will be on 16Apr2021. He would like to know if she is still able to get it. He reports that the only symptoms she has are cough, "congested head", feels like a sinus infection, and "spitting out" yellow mucus. The patient underwent lab tests and procedures which included sars-cov-2 test: tested positive on an unspecified date. Outcome of the events was unknown.  Follow-up (12Apr2021): This is a follow-up spontaneous report. No new information received.   Information about lot/batch has been requested.